View Post

North Carolina Vaccine Facility Certified for the Next Pandemic

In COVID-19, Latest News by Precision Vaccinations

If the U.S. government declares an influenza pandemic, a new vaccine production facility located in Holly Springs, North Carolina, is certified and ready to go.
New Jersey-based Seqirus announced today that the company's innovative manufacturing facility has successfully achieved all criteria required to establish domestic manufacturing capability for cell-based seasonal and pandemic influenza vaccines as outlined by the Biomedical Advanced Research and Development Authority (BARDA).

View Post

North Carolina Vaccine Facility Certified for the Next Pandemic

In Influenza Vaccine News by Influenza Vaccine

If the U.S. government declares an influenza pandemic, a new vaccine production facility located in Holly Springs, North Carolina, is certified and ready to go.
New Jersey-based Seqirus announced today that the company's innovative manufacturing facility has successfully achieved all criteria required to establish domestic manufacturing capability for cell-based seasonal and pandemic influenza vaccines as outlined by the Biomedical Advanced Research and Development Authority (BARDA).

View Post

Meningococcal Vaccination May Offer Gonorrhea Protection

In COVID-19, Latest News by Precision Vaccinations

A new study published today in Clinical Infectious Diseases suggests that a meningococcal serogroup B vaccine may offer cross-protection against gonorrhea infection.
This new research joins recent studies from Canada, Norway, and New Zealand that also indicated that meningococcal vaccines might be protective against Neisseria gonorrhoeae.
These findings are essential since Neisseria gonorrhoeae is acquiring increasing resistance to available oral antibiotics, and current screening and treatment approaches have not decreased overall gonorrhea incidence.